Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non‑small cell lung cancer

Singhi,Eric K.; Mott,Frank; Worst,Michelle; Leung,Cheuk Hong; Lee,J. Jack; Carter,Brett; Presley,Carolyn J.; Heymach,John V.; Altan,Mehmet

doi:10.3892/ol.2023.13848

Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non‑small cell lung cancer

Authors:
- Eric K. Singhi
- Frank Mott
- Michelle Worst
- Cheuk Hong Leung
- J. Jack Lee
- Brett Carter
- Carolyn J. Presley
- John V. Heymach
- Mehmet Altan
View Affiliations

Affiliations: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA, Medscape Oncology, New York, NY 10014, USA, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA, Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA, Thoracic Oncology Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
Published online on: May 3, 2023 https://doi.org/10.3892/ol.2023.13848
Article Number: 262

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunotherapy is an effective and generally well‑tolerated treatment strategy for older adult patients (aged ≥70 years) with advanced non‑small cell lung cancer (NSCLC). Unfortunately, most patients who receive immunotherapy eventually exhibit disease progression during treatment. The present study reports on a subset of older adult patients with advanced NSCLC who could effectively continue immunotherapy beyond radiographic disease progression due to perceived clinical benefit. Local consolidative radiotherapy may be used in select older adult patients to prolong the duration of immunotherapy they receive, with a particular consideration of their preexisting co‑morbidities, performance status and tolerance of potential toxicities associated with combined modality therapy. However, prospective research is needed to determine which patients benefit most from the addition of local consolidative radiotherapy, including whether type of disease progression (i.e., sites of progression, pattern of progression) and/or extent of consolidation offered (i.e., complete or incomplete) impact clinical outcomes. Further research is also warranted to determine which patients would most benefit from the continuation of immunotherapy beyond documented radiographic disease progression.

View Figures

View References

1	Luciani A, Marra A, Toschi L, Cortinovis D, Fava S, Filipazzi V, Tuzi A, Cerea G, Rossi S, Perfetti V, et al: Efficacy and safety of Anti-PD-1 immunotherapy in patients aged ≥ 75 years with non-small-cell lung cancer (NSCLC): An Italian, multicenter, retrospective study. Clin Lung Cancer. 21:e567–e571. 2020. View Article : Google Scholar : PubMed/NCBI
2	Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, et al: Clinical effectiveness and safety of anti-PD-(L)1 therapy among older adults with advanced non-small cell lung cancer. Clin Lung Cancer. 23:236–243. 2022. View Article : Google Scholar : PubMed/NCBI
3	Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol. 18:2354–2362. 2000. View Article : Google Scholar : PubMed/NCBI
4	Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103. 2000. View Article : Google Scholar : PubMed/NCBI
5	Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, et al: Gemcitabine plus best supportive care (BSC) vs. BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer. Br J Cancer. 83:447–453. 2000. View Article : Google Scholar : PubMed/NCBI
6	Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet. 374:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, et al: Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: Results of the GOIRC 02–2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol. 30:4501–4507. 2012. View Article : Google Scholar : PubMed/NCBI
8	Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, et al: Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 30:3516–3524. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, et al: Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib lung cancer trial (DELTA). J Clin Oncol. 32:1902–1908. 2014. View Article : Google Scholar : PubMed/NCBI
10	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
11	Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018. View Article : Google Scholar : PubMed/NCBI
12	Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et al: Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI
13	Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, et al: Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 23:279–291. 2022. View Article : Google Scholar : PubMed/NCBI
14	Ochoa-de-Olza M, Bourhis J, Coukos G and Herrera FG: Low-dose irradiation for reversing immunotherapy resistance: How to translate? J Immunother Cancer. 10:e0049392022. View Article : Google Scholar : PubMed/NCBI
15	Rauwerdink DJW, Molina G, Frederick DT, Sharova T, van der Hage J, Cohen S and Boland GM: Mixed response to immunotherapy in patients with metastatic melanoma. Ann Surg Oncol. 27:3488–3497. 2020. View Article : Google Scholar : PubMed/NCBI
16	Shroff GS, Strange CD, Altan M, Carter BW, Ahuja J, Godoy MCB, Truong MT and Vlahos I: Post-immunotherapy imaging in lung cancer. Clin Radiol. 77:44–57. 2022. View Article : Google Scholar : PubMed/NCBI
17	Xu Y, Li H and Fan Y: Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer. Front Oncol. 11:6428832021. View Article : Google Scholar : PubMed/NCBI
18	Reinhorn D, Jacobi O, Icht O, Dudnik E, Rotem O, Zer A and Goldstein DA: Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer. Immunotherapy. 12:235–243. 2020. View Article : Google Scholar : PubMed/NCBI
19	Ge X, Zhang Z, Zhang S, Yuan F, Zhang F, Yan X, Han X, Ma J, Wang L, Tao H, et al: Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res. 9:2391–2400. 2020. View Article : Google Scholar : PubMed/NCBI
20	Enomoto T, Tamiya A, Matsumoto K, Adachi Y, Azuma K, Inagaki Y, Kouno S, Taniguchi Y, Saijo N, Okishio K, et al: 79P-Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer. Ann Oncol. 30:xi282019. View Article : Google Scholar
21	Czarnecka AM, Sobczuk P, Rogala P, Świtaj T, Placzke J, Kozak K, Mariuk-Jarema A, Spałek M, Dudzisz-Śledź M, Teterycz P, et al: Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: A real-world evidence. Cancer Immunol Immunother. 71:1949–1958. 2022. View Article : Google Scholar : PubMed/NCBI
22	Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, et al: Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. J Immunother Cancer. 7:1962019. View Article : Google Scholar : PubMed/NCBI
23	Corbaux P, Maillet D, Boespflug A, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Dalle S, Falandry C and Péron J: Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur J Cancer. 121:192–201. 2019. View Article : Google Scholar : PubMed/NCBI
24	Nabrinsky E, Macklis J and Bitran J: A review of the abscopal effect in the era of immunotherapy. Cureus. 14:e296202022.PubMed/NCBI
25	Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, et al: Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: A randomized phase I/II trial. J Immunother Cancer. 8:e0010012020. View Article : Google Scholar : PubMed/NCBI